Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: Comparison of L-DOPA and pramipexole

Experimental Neurology

Volumn 183, Issue 1, 2003, Pages 81-86

  Kemmerer, Elyse S ^a   Desmond, Timothy J ^a,b   Albin, Roger L ^a,c   Kilbourn, Michael R ^a   Frey, Kirk A ^a,b,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

6 Hydroxydopamine (6 OHDA); Amphetamine; Methoxytetrabenazine; Parkinson's disease (PD); Rotational behavior; Striatum; Substantia nigra; Tetrabenazine; Vesicular monoamine transporter type 2 (VMAT2)

Indexed keywords

AMPHETAMINE; APOMORPHINE; DOPAMINE; ISOPROTEIN; LEVODOPA; MONOAMINE; OXIDOPAMINE; PRAMIPEXOLE; TETRABENAZINE;

ADULTHOOD; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN INJURY; BRAIN NERVE CELL; CELL CULTURE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DENSITY; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; FOREBRAIN; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MALE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; TREATMENT OUTCOME;

EID: 0041886880     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00096-7     Document Type: Article

References (44)

1. Agid Y. Levodopa is toxicity a myth? Neurology. 50:1998;858-863.
2. Albin R.L., Nichols T.E., Frey K.A. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. J. Am. Med. Assoc. 288:2002;311-312. discussion 312-313.
3. Camp D.M., Loeffler D.A., LeWitt P.A. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem. 74:2000;1229-1240.
4. Carter A.J., Muller R.E. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur. J. Pharmacol. 200:1991;65-72.
5. Carvey P.M., Pieri S., Ling Z.D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J. Neural Transm. 104:1997;209-228.
6. Clarke C.E. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov. Disord. 10:1995;250-256.
7. Datla K.P., Blunt S.B., Dexter D.T. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Disord. 16:2001;424-434.
8. Engber T.M., Susel Z., Kuo S., Chase T.N. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization. J. Neurosci. 10:1990;3889-3895.
9. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann. Neurol. 43:1998;551-554.
10. Frey K.A., Kilbourn M.R., Robinson T.E. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur. J. Pharmacol. 334:1997;273-279.
11. Han S.K., Mytilineou C., Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66:1996;501-510.
12. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626:1993;167-174.
13. Ingham C.A., Hood S.H., van Maldegem B., Weenink A., Arbuthnott G.W. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp. Brain Res. 93:1993;17-27.
14. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
15. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., Taniguchi T. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417:2001;59-67.
16. Kitamura Y., Kohno Y., Nakazawa M., Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn. J. Pharmacol. 74:1997;51-57.
17. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47:2000;493-503.
18. Lyras L., Zeng B.Y., McKenzie G., Pearce R.K., Halliwell B., Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J. Neural Transm. 109:2002;53-67.
19. Marek K., Seibyl J., Shoulson I., Holloway R., Kieburtz K., McDermott M., Kamp C., Shinaman A., Fahn S., Lang A., Weiner W., Welsh M. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J. Am. Med. Assoc. 287:2002;1653-1661.
20. Mena M.A., Casarejos M.J., Carazo A., Paino C.L., Garcia de Yebenes J. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. NeuroReport. 7:1996;441-445.
21. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43:1998;561-575.
22. Mytilineau C., Han S.K., Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J. Neurochem. 61:1993;1470-1478.
23. Nitsch C., Riesenberg R. Synaptic reorganisation in the rat striatum after dopaminergic deafferentation: an ultrastructural study using glutamate decarboxylase immunocytochemistry. Synapse. 19:1995;247-263.
24. Ogawa N., Asanuma M., Kondo Y., Kawada Y., Yamamoto M., Mori A. Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci. Lett. 171:1994;55-58.
25. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology. 40:(Suppl.):1990;32-37. discussion 37-39.
26. Olanow C.W., Jenner P., Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44:1998;S167-S174.
27. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
28. 3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography. J. Neurosci. 3:1983;1189-1198.
29. Pramipexole vs. levodopa as initial treatment for Parkinson disease a randomized controlled trial . J. Am. Med. Assoc. 284:2000;1931-1938.
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed:1986;Academic Press, Orlando, FL.
31. Perry T.L., Yong V.W., Ito M., Foulks J.G., Wall R.A., Godin D.V., Clavier R.M. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J. Neurochem. 43:1984;990-993.
32. Piercey M.F., Walker E.L., Feldpausch D.L., Camacho-Ochoa M. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci. Lett. 219:1996;138-140.
33. Rajput A.H. The protective role of levodopa in the human substantia nigra. Adv. Neurol. 86:2001;327-336.
34. Sethy V.H., Wu H., Oostveen J.A., Hall E.D. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754:1997;181-186.
35. Suzuki M., Desmond T.J., Albin R.L., Frey K.A. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann. Neurol. 51:2002;767-771.
36. Trugman J.M., Wooten G.F. The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res. 379:1986;264-274.
37. Trugman J.M., Wooten G.F. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J. Neurosci. 7:1987;2927-2935.
38. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294:1995;577-583.
39. 3H]methoxytetrabenazine a high specific activity ligand for estimating monoaminergic neuronal integrity . Neuroscience. 68:1995;955-962.
40. Vu T.Q., Ling Z.D., Ma S.Y., Robie H.C., Tong C.W., Chen E.Y., Lipton J.W., Carvey P.M. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J. Neural Transm. 107:2000;159-176.
41. Weiner W.J. Is levodopa toxic? Arch. Neurol. 57:2000;408-410.
42. Zou L., Jankovic J., Rowe D.B., Xie W., Appel S.H., Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 64:1999;1275-1285.
43. Zou L., Xu J., Jankovic J., He Y., Appel S.H., Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 281:2000;167-170.
44. Zucker M., Weizman A., Harel D., Rehavi M. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat substantia nigra and prefrontal cortex induced by psychotropic drugs. Neuropsychobiology. 44:2001;187-191.